GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Coloplast A/S (OTCPK:CLPBY) » Definitions » EV-to-FCF

Coloplast A/S (Coloplast A/S) EV-to-FCF : 50.35 (As of Apr. 25, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Coloplast A/S EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Coloplast A/S's Enterprise Value is $31,241 Mil. Coloplast A/S's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $620 Mil. Therefore, Coloplast A/S's EV-to-FCF for today is 50.35.

The historical rank and industry rank for Coloplast A/S's EV-to-FCF or its related term are showing as below:

CLPBY' s EV-to-FCF Range Over the Past 10 Years
Min: 24.42   Med: 45.8   Max: 80.02
Current: 52.37

During the past 13 years, the highest EV-to-FCF of Coloplast A/S was 80.02. The lowest was 24.42. And the median was 45.80.

CLPBY's EV-to-FCF is ranked worse than
72.31% of 372 companies
in the Medical Devices & Instruments industry
Industry Median: 25.71 vs CLPBY: 52.37

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), Coloplast A/S's stock price is $12.58. Coloplast A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.322. Therefore, Coloplast A/S's PE Ratio for today is 39.07.


Coloplast A/S EV-to-FCF Historical Data

The historical data trend for Coloplast A/S's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coloplast A/S EV-to-FCF Chart

Coloplast A/S Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.24 56.06 65.07 46.11 62.52

Coloplast A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.68 61.01 65.97 62.52 45.34

Competitive Comparison of Coloplast A/S's EV-to-FCF

For the Medical Instruments & Supplies subindustry, Coloplast A/S's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coloplast A/S's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Coloplast A/S's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Coloplast A/S's EV-to-FCF falls into.



Coloplast A/S EV-to-FCF Calculation

Coloplast A/S's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=31241.365/620.468
=50.35

Coloplast A/S's current Enterprise Value is $31,241 Mil.
Coloplast A/S's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $620 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coloplast A/S  (OTCPK:CLPBY) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Coloplast A/S's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=12.58/0.322
=39.07

Coloplast A/S's share price for today is $12.58.
Coloplast A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.322.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Coloplast A/S EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Coloplast A/S's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Coloplast A/S (Coloplast A/S) Business Description

Address
Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

Coloplast A/S (Coloplast A/S) Headlines

From GuruFocus

Coloplast A/S's Dividend Analysis

By GuruFocus Research 12-07-2023